All In Biotech

Drug Trial Radar · NCT06667076

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

May 23, 2029

Study completion Dec 26, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AmivantamabDrug

    Amivantamab will be administered.

  • LazertinibDrug

    Lazertinib tablet will be administered.

  • Chemotherapy: PemetrexedDrug

    Pemetrexed will be administered.

  • Chemotherapy: CarboplatinDrug

    Carboplatin will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 4 Years and 6 months

Locations

205 sites in 14 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, PC

    Daphne, Alabama · Active not recruiting

  • Clearview Cancer Institute

    Huntsville, Alabama · Completed

  • City of Hope Phoenix

    Goodyear, Arizona · Active not recruiting

  • The Oncology Institute of Hope and Innovation

    Cerritos, California · Active not recruiting

  • City of Hope Corona

    Corona, California · Active not recruiting

  • City of Hope

    Duarte, California · Active not recruiting

  • Oncology Physicians Network Healthcare

    Glendale, California · Completed

  • Los Angeles Cancer Network

    Glendale, California · Active not recruiting

  • Glendale Adventist Medical Center

    Glendale, California · Completed

  • Marin Cancer Center

    Greenbrae, California · Completed

  • City of Hope Seacliff

    Huntington Beach, California · Active not recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Active not recruiting

  • University of California San Diego Health

    La Jolla, California · Active not recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • City of Hope Long Beach Elm

    Long Beach, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Active not recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Active not recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Active not recruiting

  • Providence Medical Foundation

    Mission Viejo, California · Active not recruiting

  • Valkyrie Clinical Trials Murrieta

    Murrieta, California · Active not recruiting

  • Kaiser Permanente Oakland Medical Center

    Oakland, California · Completed

  • St. Joseph Hospital Center for Cancer Prevention and Treatment

    Orange, California · Completed

  • University of California Irvine

    Orange, California · Active not recruiting

  • Sutter Health Palo Alto Medical Foundation

    Palo Alto, California · Completed

  • Kaiser Permanente Roseville Medical Center

    Roseville, California · Completed

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Active not recruiting

  • Sutter Institute for Medical Research

    Sacramento, California · Completed

  • California Pacific Medical Center

    San Francisco, California · Completed

  • Kaiser Permanente San Francisco Medical Center

    San Francisco, California · Completed

  • UCSF Zuckerberg San Francisco General Hospital

    San Francisco, California · Active not recruiting

  • Sansum Clinic

    Santa Barbara, California · Active not recruiting

  • Kaiser Permanente Santa Clara Medical Center

    Santa Clara, California · Active not recruiting

  • Providence Medical Foundation 1

    Santa Rosa, California · Active not recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • Kaiser Permanente Northern California

    Vallejo, California · Active not recruiting

  • Kaiser Permanente Walnut Creek Medical Center

    Walnut Creek, California · Active not recruiting

  • John Muir Health Clinical Research Center

    Walnut Creek, California · Active not recruiting

  • National Jewish Health

    Denver, Colorado · Completed

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.